The Atriva Management
Rainer Lichtenberger, Ph.D.,
30 years management in life science Industry, VP Global Marketing, Merck, EVP ratiopharm group for New Business. Since 16 years CEO experience in SME and biotech, raised € 80 Mn funds, involved in € 200+ Mn deal volume.
Prof. Oliver Planz, Ph.D.,
CSO, Head of Preclinical Research
Chair of Scientific Board
Co-inventor of the technology, expert in antiviral research and translational preclinical R&D up to clinical studies. Advises the WHO on antiviral strategies against influenza. More than 150 publications and over 40 patents
Stephan Stenglein, M.D.,
CMO & EVP Clinical Development
Physician trained in Clinical and Molecular Virology with 20 years of accomplishments in pharma, medical device and vaccine development. Previous global management positions with Novartis and AstraZeneca.
Christian Wallasch, Ph.D., CDO/COO & EVP
20 years senior management experience (COO, CEO) in SMEs (Axxima, GPC Biotech and public companies (Intercel/Valneva)). Proven track record in the preclinical/clinical development of kinase inhibitors and vaccines, project-management and -execution.
Cees Stouten, M.Sc.,
SVP Chemistry Manufacturing Controls,
Site Manager Atriva Therapeutics BV
Accomplished CMC manager with long-standing and deep experience along the entire development, manufacturing and control value chain,
more than 20 years industry experience
Björn Cochlovius, Ph.D.,
VP Business Development
20 years leadership positions in SMEs (Head R&D Affitech, CEO OnTarget) and global leadership positions in big pharma (Roche, Otsuka, Abbvie). Working experiences in Europe and Asia. Background in R&D, Business Development, M&A, Financing. Several Board seats and chairmanships.